Followers | 3 |
Posts | 350 |
Boards Moderated | 0 |
Alias Born | 01/14/2010 |
Wednesday, February 01, 2017 9:19:30 AM
PR NewswireFebruary 1, 2017
PUNE, India, February 1, 2017 /PRNewswire/ --
According to a new market research report "3D Bioprinting Market by Technology (Microextrusion, Inkjet, Laser, Magnetic), Material (Cells, Hydrogels, Extracellular Matrices, Biomaterials), Application (Clinical (Bone, Cartilage, Skin) & Research (Regenerative Medicine)) - Global Forecasts to 2021", published by MarketsandMarkets, This report studies the global 3D Bioprinting Market over the forecast period of 2016 to 2021. This market is expected to reach USD 1,332.6 Million by 2021, at CAGR of 26.5% from 2016 to 2021.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 74 market data Tables and 39 Figures spread through 143 Pages and in-depth TOC on "3D Bioprinting Market"
http://www.marketsandmarkets.com/Market-Reports/3d-bioprinting-market-170201787.html
Early buyers will receive 10% customization on this report.
Key factors such as rising demand for organ transplantation, growing R&D in 3D bioprinting, increasing public and private investments in research, and rising use of 3D bioprinting in drug discovery are driving the growth of this market. However, the limitations of biomaterial-based products, lack of complete automation in 3D bioprinting, and socio-ethical concerns related to the use of 3D bioprinted products are the major challenges in this market.
By technology, the global 3D Bioprinting Market is segmented into four broad categories, namely, microextrusion, inkjet, laser, and magnetic 3D bioprinting. The microextrusion 3D bioprinting technology is estimated to command the largest share of the market in 2016, due to its affordability, among other factors.
On the basis of application, the market is segmented into clinical applications (including skin, bone & cartilage, and blood vessels) and research applications (including drug research, regenerative medicine, and 3D cell culture).
Speak To Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=170201787
On the basis of procedure, the market is segmented into thoracotomy and minimally invasive surgeries. The The research applications segment holds the largest share in the 3D bioprinting market; it is projected to witness high growth during the forecast period. Increasing initiatives by market players and university scientists in the 3D bioprinting field form the major factor driving the growth of this segment.
Based on material, the 3D Bioprinting Market is further segmented into extracellular matrices, hydrogels, living cells, and biomaterials. The living cells segment is expected to account for the largest share of the market in 2016. Increasing R&D initiatives for the use of living cells in 3D bioprinting form one of the major factors driving the growth of the market.
As of 2016, North America holds the largest share of the global 3D bioprinting market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. A number of factors such as increase in overall and stem cell research activity, growing demand for organ transplantation, and rising initiatives by market players are propelling the growth of the Asia-Pacific 3D bioprinting market.
Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=170201787
As of 2015, the 3D Bioprinting Market is dominated by Organovo Holdings Inc. (U.S.), EnvisionTEC GmbH (Germany), and Nano3D Biosciences, Inc. (U.S.). Other players in this market include Cyfuse Biomedical K.K. (Japan), BioBots (U.S.), Aspect Biosystems Ltd. (Canada), 3Dynamic Systems Ltd. (U.K.), regenHU Ltd (Switzerland), Cellink (Sweden), Regenovo Biotechnology Co., Ltd. (China), Poietis (France), and GeSiM (Germany).
Browse Related Reports:
3D Printing Medical Devices Market by Component (3D Printers, 3D Bioprinters, Materials, Services & Software), Technology (EBM, LBM, Photopolymerization, 3DP, and DD) & by Medical Products (Surgical Guides, Equipment, Implant) - Global Forecast to 2020.
http://www.marketsandmarkets.com/Market-Reports/3d-printing-medical-devices-market-90799911.html
3D Cell Culture Market by Technology (Scaffold Based, Scaffold Free), Application (Cancer Cell Research, Cell-based Assays/Toxicity Screening), End- Users (Biotechnology & Pharmaceuticals Industries) and Geography- Global Forecast to 2021.
http://www.marketsandmarkets.com/Market-Reports/3d-cell-culture-market- 191072847.html
Recent ONVO News
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/14/2024 04:45:20 PM
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) • GlobeNewswire Inc. • 05/14/2024 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:00:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/10/2024 09:15:22 PM
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering • GlobeNewswire Inc. • 05/09/2024 12:00:12 AM
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/09/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2023 11:05:02 AM
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results • GlobeNewswire Inc. • 12/06/2023 01:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:41:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:40:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:34:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:41:04 PM
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/13/2023 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:34 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM